Adipogen/Salinosporamide A/AG-CN2-0444-C100/100 µg
商品编号：
AG-CN2-0444-C100
品牌：
Adipogen Inc
市场价：
¥3800.00
美元价：
2280.00
产品分类：
其他试剂
公司分类：
Other_reagents
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
| ProductDetails | |
|---|---|
| Synonyms | SalA;Marizomib;NPI-0052 |
| ProductType | Chemical |
| Properties | |
| Formula | C15H20ClNO4 |
| MW | 313.8 |
| CAS | 437742-34-2 |
| Source/HostChemicals | IsolatedfromSalinosporatropica. |
| PurityChemicals | ≥95%(HPLC) |
| Appearance | Whitesolid. |
| Solubility | SolubleinDMSO.Donotdissolveinmethanolorethanol. |
| OtherProductData | Note:Werecommendtousefreshsolutions.AliquotsshouldbepreparedinDMSOandstoredat-20°C. |
| InChiKey | NGWSFRIPKNWYAO-SHTIJGAHSA-N |
| ShippingandHandling | |
| Shipping | BLUEICE |
| ShortTermStorage | +4°C |
| LongTermStorage | -20°C |
| HandlingAdvice | Keepunderinertgas. Protectfromlight. Protectfrommoistureandoxygen. |
| Use/StABIlity | Stableforatleast1yearafterreceiptwhenstoredat-20°C. |
| Documents | |
| MSDS |  DownloadPDF |
| ProductSpecificationSheet | |
| Datasheet | DownloadPDF |
- Potent,irreversIBLeinhibitorofallthe3proteolyticactivitiesofthemammalian20Sproteasome.
- β5subunit:chymotrypsin-like(EC50=3.5nM)
- β2subunit:trypsin-like(EC50=28nM)
- β1subunit:caspase-likeorpeptidyl-glutamylpeptide-hydrolyzing(PGPH)(EC50=430nM)
- Potentanticancercompound.
- Triggersapoptosis,withdistinctproteasomeactivityandmechanismofactioncomparedtobortezomib(Velcade)(Prod.No.AG-CR1-3602).
- MostpotentsuppressorofNF-κBactivation,comparedwithbortezomib,MG-132(Prod.No.AG-CP3-0011),N-acetyl-leucyl-leucyl-norleucinal(ALLN)andlactacystin(Prod.No.AG-CN2-0104).
- InhibitorofTNF-α,IL-1,IL-6,ICAM-1andVEGFsynthesis.
- Displaysalongerinhibitiondurationthanbortezomib.
- Potentantileukemicactivityagainstbortezomib-resistantleukemiacells.
ProductReferences
- SalinosporamideA:ahighlycytotoxicproteasomeinhibitorfromanovelmicrobialsource,amarinebacteriumofthenewgenussalinospora:R.H.Feling,etal.;Angew.Chem.Int.Ed.Engl.42,355(2003)
- Structure-activityrelationshipstudiesofsalinosporamideA(NPI-0052),anovelmarinederivedproteasomeinhibitor:V.R.Macherla,etal.;J.Med.Chem.48,3684(2005)
- AnovelorallyactiveproteasomeinhibitorinducesapoptosisinmultiplemyelomacellswithmechanismsdistinctfromBortezomib:D.Chauhan,etal.;CancerCell8,407(2005)
- CrystalstructuresofSalinosporamideA(NPI-0052)andB(NPI-0047)incomplexwiththe20Sproteasomerevealimportantconsequencesofbeta-lactoneringopeningandamechanismforirreversiblebinding:M.Groll,etal.;JACS128,5136(2006)
- NPI-0052enhancestumoricidalresponsetoconventionalcancertherapyinacoloncancermodel:J.C.Cusack,etal.;Clin.CancerRes.12,6758(2006)
- ComparisonofbiochemicalandBIOLOGicaleffectsofML858(salinosporamideA)andbortezomib:M.J.Williamson,etal.;Mol.CancerTher.5,3052(2006)
- SalinosporamideA(NPI-0052)potentiatesapoptosis,suppressesosteoclastogenesis,andinhibitsinvasionthroughdown-modulationofNF-κB-regulatedgeneproducts:K.S.Ahn,etal.;Blood110,2286(2007)
- AmechaNISTicandkineticstudyofthebeta-lactonehydrolysisofSalinosporamideA(NPI-0052),anovelproteasomeinhibitor:N.Denora,etal.;J.Pharm.Sci.96,2037(2007)
- CombinationofproteasomeinhibitorsbortezomibandNPI-0052triggerinvivosynergisticcytotoxicityinmultiplemyeloma:D.Chauhan,etal.;Blood111,1654(2008)
- DiscoveryanddevelopmentoftheanticanceragentsalinosporamideA(NPI-0052):W.Fenical,etal.;Bioorg.Med.Chem.17,2175(2009)
- Generatingagenerationofproteasomeinhibitors:frommicrobialfermentationtototalsynthesisofsalinosporamidea(marizomib)andothersalinosporamides:B.C.Potts&K.S.Lam;Mar.Drugs8,835(2010)(Review)
- Salinosporamidenaturalproducts:Potent20Sproteasomeinhibitorsaspromisingcancerchemotherapeutics:T.A.Gulder&B.S.Moore;Angew.Chem.Int.Ed.Engl.49,9346(2010)(Review)
- Marizomib,aproteasomeinhibitorforallseasons:preclinicalprofileandaframeworkforclinicaltrials:B.C.Potts,etal.;Curr.CancerDrugTargets11,254(2011)
- Proteasomeregulatormarizomib(NPI-0052)exhibitsprolongedinhibition,attenuatedefflux,andgreatercytotoxicitythanitsreversibleanalogs:A.Obaidat,etal.;J.Pharmacol.Exp.Ther.337,479(2011)
- Molecularmechanismsofacquiredproteasomeinhibitorresistance:A.J.Kale&B.S.Moore;J.Med.Chem.55,10317(2012)
- AntileukemicactivityandmechanismofdrugresistancetothemarineSalinisporatropicaproteasomeinhibitorsalinosporamideA(Marizomib):D.Niewerth,etal.;Mol.Pharmacol.86,12(2014)
品牌介绍
Adipogen公司由三个子公司组成，分别是Adipogen,Inc.(韩国),AdipogenSA(瑞士)和 AdipogenCorporation(美国圣地亚哥)。总部设在美国，运营总部在瑞士利斯塔尔。Adipogen公司专门从事生命科学研究试剂的开发，如癌症、免疫、炎症、代谢疾病（糖尿病、肥胖）、干细胞和神经退行性疾病等领域。其重点关注开发创新优质的ELISA试剂盒。另外，也可提供抗体和蛋白产品，Adipogen拥有自己的化学实验室，致力于开发创新型小分子化合物。
联络我们
